Acrux (ACR) AI Stock Analysis

• Market Cap: AU$6.16M
• Dividend Yield: N/A
• Average Volume (3M): 206.74K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.28
• Revenue Growth: -76.63%
• EPS Growth: 12.00%
• Country: AU
• Employees: 43
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): >-0.01
• Shares Outstanding: 410,608,520
• 10 Day Avg. Volume: 171,483
• 30 Day Avg. Volume: 206,739
• PEG Ratio: 0.06
• Price to Book (P/B): 5.51
• Price to Sales (P/S): 4.73
• P/FCF Ratio: -1.03
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): <0.01
• Revenue Forecast (FY): AU$18.01M

• Rating: 42 Neutral
• Price Target: AU$0.01 ▼(-35.00% Downside)

Acrux's overall stock score is primarily impacted by its weak financial performance, characterized by persistent losses and high leverage. Technical analysis provides mixed signals, with no strong momentum. Valuation metrics are concerning, with a negative P/E ratio and no dividend yield. These factors collectively suggest a high-risk investment with significant challenges ahead.

Positive Factors

Revenue Growth

The significant revenue growth indicates potential market expansion and increased demand for Acrux's products, which can enhance long-term business prospects.

Gross Profit Margin

An improved gross profit margin suggests better cost management and pricing strategy, which can contribute to future profitability if maintained.

Product Innovation

Acrux's focus on innovative drug delivery systems positions it well in the biopharmaceutical industry, potentially driving long-term growth through new product development.

Negative Factors

High Leverage

High leverage increases financial risk and limits flexibility, potentially impacting Acrux's ability to invest in growth opportunities or weather economic downturns.

Negative Cash Flows

Persistent negative cash flows indicate liquidity challenges, which can constrain Acrux's operational capabilities and investment in future growth.

Profitability Challenges

Ongoing profitability challenges reflect operational inefficiencies and high costs, which could hinder Acrux's ability to achieve sustainable financial health.

Acrux Business Overview & Revenue Model

Company Description

Acrux Limited (ACR) is a biopharmaceutical company based in Australia, specializing in the development and commercialization of innovative drug delivery technologies and pharmaceutical products. The company operates primarily in the healthcare sector, focusing on transdermal delivery systems, which enable medications to be absorbed through the skin. Acrux's core products include various transdermal patches and formulations designed to improve patient adherence and therapeutic outcomes in areas such as hormone replacement therapy and pain management.

How the Company Makes Money

Acrux generates revenue through the commercialization of its proprietary drug delivery technologies and products. The company earns money by selling its transdermal patches directly to pharmaceutical partners and healthcare providers, as well as by licensing its technologies to other companies for the development of new products. Key revenue streams include product sales, licensing agreements, and royalties from partnered products that utilize Acrux's technology. Strategic partnerships with established pharmaceutical companies enhance Acrux's market reach and provide additional revenue opportunities through collaborative development and marketing efforts.

Acrux Financial Statement Overview

Summary

Acrux faces significant financial challenges, with persistent losses, high leverage, and negative cash flows. Despite some revenue growth and an improved gross profit margin, the company's profitability and cash flow issues pose substantial risks. The high debt-to-equity ratio and negative return on equity further highlight financial instability.

Income Statement

Acrux's income statement reveals significant challenges, with consistently negative net profit margins and EBIT margins over the years. Although there was a notable revenue growth of 48.38% in 2025, the company still reported a substantial net loss. The gross profit margin improved to 100% in 2025, but this is overshadowed by the negative profitability metrics, indicating operational inefficiencies and high costs relative to revenue.

Balance Sheet

The balance sheet shows a concerning debt-to-equity ratio of 3.55 in 2025, indicating high leverage and potential financial risk. Return on equity is negative, reflecting ongoing losses. The equity ratio has decreased, suggesting a weakening financial position. Despite these issues, the company has managed to maintain a positive equity base, which provides some stability.

Cash Flow

Cash flow analysis highlights negative operating and free cash flows, with a slight improvement in free cash flow growth in 2025. The operating cash flow to net income ratio is negative, indicating cash flow challenges. The free cash flow to net income ratio is close to 1, suggesting that cash outflows are closely aligned with net losses, which is a concern for liquidity.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	1.19M	1.19M	5.09M	8.43M	1.72M	1.34M
Gross Profit	-1.12M	1.19M	1.13M	1.95M	-4.65M	-7.59M
EBITDA	-8.76M	-5.17M	-8.06M	-2.79M	-12.29M	-15.59M
Net Income	-5.95M	-5.95M	-5.80M	-764.00K	-9.83M	-12.63M
Balance Sheet
Total Assets	7.22M	7.22M	8.96M	14.30M	15.27M	24.20M
Cash, Cash Equivalents and Short-Term Investments	863.00K	863.00K	2.94M	6.23M	5.83M	15.27M
Total Debt	3.63M	3.63M	3.70M	2.35M	2.08M	2.23M
Total Liabilities	6.20M	6.20M	5.69M	5.60M	6.18M	5.73M
Stockholders Equity	1.02M	1.02M	3.28M	8.70M	9.09M	18.47M
Cash Flow
Free Cash Flow	-5.48M	-5.48M	-4.58M	584.00K	-9.28M	-11.52M
Operating Cash Flow	-5.47M	-5.47M	-4.30M	703.00K	-8.82M	-11.41M
Investing Cash Flow	-5.00K	-5.00K	-276.00K	-119.00K	-465.00K	-102.00K
Financing Cash Flow	3.39M	3.39M	1.29M	-183.00K	-155.00K	17.58M

Acrux Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.02
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:ACR, the sentiment is Positive. The current price of 0.02 is above the 20-day moving average (MA) of 0.02, above the 50-day MA of 0.01, and above the 200-day MA of 0.02, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 55.38 is Neutral, neither overbought nor oversold. The STOCH value of 50.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:ACR.

Acrux Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IXC	57 Neutral	AU$8.64M	-18.25	-8.72%	―	―	71.10%
NSB	54 Neutral	AU$46.56M	-11.11	-16.65%	―	―	-672.73%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ACR	42 Neutral	AU$6.16M	―	-270.27%	―	-76.63%	12.00%
CHM	42 Neutral	AU$10.93M	-1.69	-469.35%	―	―	46.28%
MEM	39 Underperform	AU$10.46M	-3.57	-90.15%	―	-93.83%	20.00%

Acrux Corporate Events

Acrux Reports Strong Profit Share Growth and Revenue Acceleration

Acrux Limited reported a significant increase in its profit share income for the September quarter, surpassing the total income of the previous financial year. The company’s revenue growth is driven by products launched in FY25, with notable contributions from Nitroglycerin ointment and Dapsone gels. Additionally, Acrux received a substantial R&D Tax Incentive Rebate from the Australian Tax Office and repaid short-term advances from Radium Capital. The company’s strategic focus on its portfolio of topical generics is expected to continue supporting revenue growth in FY26.

Acrux Limited Reports Robust Quarterly Growth and Strategic Expansion Plans

Acrux Limited reported a significant increase in its September quarterly profit share income, surpassing the total income of the previous financial year. This growth is attributed to the successful market penetration of its recently launched products, including Nitroglycerin Ointment and Dapsone Gel, which have achieved substantial market shares. The company also received a $3.04 million R&D Tax Incentive Rebate from the Australian Tax Office, which facilitated the repayment of short-term advances from Radium Capital. Acrux’s strategic focus on expanding its portfolio of generic products and exploring international markets is expected to drive further revenue growth and enhance its industry positioning.

Acrux Limited Announces Key Resolutions for Upcoming AGM

Acrux Limited has announced its Annual General Meeting (AGM) scheduled for November 25, 2025, where shareholders will discuss key resolutions including the re-election of Dr. Geoff Brooke as a director, the issuance of rights to non-executive directors, and options to the CEO under the company’s Omnibus Equity Plan. Additionally, shareholders will consider approving a 10% placement capacity for equity securities, which could impact the company’s capital structure and shareholder value.

Acrux Announces AGM Date and Director Nominations Deadline

Acrux Limited has announced the date for its upcoming Annual General Meeting (AGM), scheduled for November 25, 2025, in Melbourne. A key agenda item will be the election of directors, with nominations accepted until October 10, 2025. This meeting is significant for stakeholders as it will shape the company’s leadership and potentially influence its strategic direction.

Acrux Secures $3.04 Million R&D Tax Rebate for FY25

Acrux Limited has received a $3.04 million R&D Tax Incentive rebate from the Australian Tax Office for FY25, which has allowed them to repay their short-term funding facility from Radium Capital. This rebate underscores Acrux’s commitment to investing in research and development in Australia, aligning with the government’s vision of fostering a future driven by Australian science.

Acrux Ltd Releases Corporate Governance Statement for FY 2025

Acrux Ltd has released its Appendix 4G and Corporate Governance Statement for the financial year ending June 30, 2025. This release, approved by the Board of Directors, highlights the company’s adherence to ASX Corporate Governance Council’s principles and recommendations, reflecting its commitment to transparency and regulatory compliance.